DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction:

Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for diabetes, could interrupt this gut–brain disease pathway.

Why was this study needed?

Although DPP-4 inhibitors have shown neuroprotective signals in previous studies, the underlying mechanisms remain unclear. Understanding whether these drugs can modify gut inflammation, α-synuclein propagation, and gut microbiota could open new opportunities for drug repurposing in PD.

What did the study show?

• Sitagliptin reduced intestinal inflammation by suppressing TLR2-mediated immune activation.
• Treatment significantly decreased α-synuclein accumulation in the gut, vagus nerve, and brain.
• Neuronal loss in the medulla and midbrain was reduced, with corresponding improvement in motor function.
• Sitagliptin favorably altered the gut microbiome toward a profile associated with reduced PD pathology.
• The neuroprotective effects persisted even after GLP-1 receptor blockade, suggesting mechanisms independent of GLP-1 signaling.
• The findings identify the gut–brain axis as a potential therapeutic target for DPP-4 inhibitors.

Clinical Impact:

This study supports the concept of repurposing DPP-4 inhibitors as disease-modifying therapies for Parkinson's disease. By targeting gut inflammation, α-synuclein propagation, and microbiome dysbiosis, these agents may offer benefits beyond glucose control, although human clinical trials are needed.

Take-Home Message:

Sitagliptin attenuated gut inflammation, reduced α-synuclein spread from the gut to the brain, and improved neurological outcomes in a Parkinson's disease model. These findings highlight DPP-4 inhibitors as promising candidates for gut–brain axis–targeted therapy in Parkinson's disease.